A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)

• Status: Recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

A clinical study to evaluate the long-term safety of Sodium Oligomannate Capsules (GV-971)

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Greenvalley Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• Subjects eligible for this study must meet all of the following criteria:

1. ≥18 years of age;

2. Signed informed consent form;

3. Patients receiving GV-971 treatment prescribed by clinicians;

Exclusion Criteria:

• A subject may be excluded from participation in the study if any of the following apply:

1. Patients who may be allergic to Sodium Oligomannate Capsules as judged by the investigator;

2. Female participants who are pregnant or lactating;

3. Patients who cannot cooperate to complete the follow-up inquiries;

4. Any other diseases or conditions that are inappropriate to participate in this clinical trial in the opinion of the investigator.